Citius Oncology
CTOR
15 hedge funds and large institutions have $34.3M invested in Citius Oncology in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$5.07M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$4.06M |
| 3 |
GCL
Glazer Capital LLC
New York
|
+$3.92M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$3.55M |
| 5 |
MSU
Mizuho Securities USA
New York
|
+$3.07M |
Top Sellers
CTOR Hedge Fund Activity: Q4 2022 in Review
15 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q4 2022, worth a combined $34.3M.
Buyers outnumbered sellers: 15 funds opened new CTOR positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $5.07M.
- 15 institutional investors held Citius Oncology (CTOR) as of Q4 2022, up from 0 in Q3 2022.
- Funds reported $34.3M of Citius Oncology stock for Q4 2022.
- 15 funds opened new Citius Oncology positions in Q4 2022 and 0 closed out, a net change of +15 holders.
- The largest Citius Oncology buyer in Q4 2022 was Hudson Bay Capital Management, an estimated $5.07M added.
Based on aggregated 13F filings for Q4 2022.